Moleculin Biotech Inc (MBRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.02M
Last updated: Nov 17, 2026 at 4:10 PM ET
Moleculin Biotech Inc (MBRX) Statistics
Moleculin Biotech (MBRX) has a market cap of $8.02M and an enterprise value of $734.80K. Revenue fell 100.00% over the last 12 months from the 12 months before. It holds $7.29M more cash than debt, 90.84% of its market cap.
Total Valuation
Enterprise value is 90.84% below the market cap, as cash exceeds debt.
| Market Cap | $8.02M |
|---|---|
| Enterprise Value | $734.80K |
| Latest price (Nov 17, 2026) | $6.98 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 0.4x |
|---|---|
| P/TBV Ratio | 1.6x |
Price Statistics
The stock is down 96.78% over 52 weeks and trades 27.59% below its 50-day average.
| Beta (1Y) | 0.57 |
|---|---|
| 52-Week Change | -96.78% |
| 1-Month Change | +31.70% |
| 3-Month Change | -38.99% |
| 6-Month Change | -85.15% |
| 5-Year Change | -99.96% |
| 10-Year Change | -99.99% |
| Total Return (1Y) | -96.78% |
| Total Return (3Y CAGR) | -88.35% |
| Total Return (5Y CAGR) | -78.82% |
| Return vs SPY (1Y) | -108.24% |
| Max Drawdown (1Y) | -97.58% |
| Max Drawdown (3Y) | -99.93% |
| Sharpe Ratio (1Y) | -2.08 |
| Correlation with SPY (1Y) | 0.05 |
| 50-Day Average | $9.64 |
| 200-Day Average | $35.55 |
| 52-Week Range | $3.23 to $227.05 |
| RSI (14 Days) | 37.6 |
| Average Volume (20 Days) | 36.24K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.37x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.37x |
|---|---|
| Quick Ratio | 1.37x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -145.34% and return on assets is -101.55% over the last 12 months.
| Return on Equity (ROE) | -145.34% |
|---|---|
| Return on Assets (ROA) | -101.55% |
| ROA (5Y Average) | -90.58% |
Scores
MBRX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$9.00K |
| Operating Income | -$29.58M |
| Pretax Income | -$21.12M |
| Net Income | -$21.06M |
| EBITDA | -$21.11M |
| Reported EPS (TTM) | -$9.70 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 69.86% of the $20.74M in total assets.
| Cash and Equivalents | $7.29M |
|---|---|
| Total Debt | $0 |
| Net Cash | $7.29M |
| Net Cash Per Share | $9.62 |
| Working Capital | $2.28M |
| Shareholder Equity | $14.49M |
| Book Value Per Share | $19.12 |
| Tangible Book Value | $3.34M |
| Tangible Book Per Share | $4.41 |
| Total Assets | $20.74M |
| Total Liabilities | $6.25M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$27.10M |
|---|---|
| FCF Per Share | -$26.59 |
| Depreciation and Amortization | $33.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
MBRX does not pay a dividend.
| Buyback Yield | -463.30% |
|---|---|
| Shareholder Yield | -463.30% |
Stock Splits
The last split was a 1-for-20 reverse split on Oct 20, 2026.
| Last Split Date | Oct 20, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MBRX
What is MBRX's market cap?
Moleculin Biotech has a market cap of $8.02M. Its enterprise value, which adds debt and subtracts cash, is $734.80K.
How many shares of MBRX are outstanding?
Moleculin Biotech has 757.86K shares outstanding.
Does MBRX pay a dividend?
No. Moleculin Biotech does not pay a dividend.
How much debt does MBRX have?
Moleculin Biotech has $0 of total debt and $7.29M of cash and equivalents, a net cash position of $7.29M.
MBRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors